a. Reducing Radioiodine Treatment in Papillary Thyroid Cancer. RAILESS

Reducing Radioiodine Treatment in Low Risk Papillary Thyroid Cancer

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06271044

Enrollment

Registered

2024-02-21

Start date

2014-10-31

Completion date

2027-12-31

Last updated

2024-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

to Omit Radioiodine Treatment Safely in Patients With Low -Risk Papillary Thyroid Cancer With Seize of 11-20mm

Keywords

radioiodine treatment, low risk thyroid cancer, papillary thyroid cancer

Brief summary

To study if its is safe to reduce the amount of postoperative treatments in those patients, who have been operated on because of a low-risk intrathyroidal papillary thyroid cancer with diameter of 11-20mm, and in whom postoperative thyroglobulin levels are of low level.

Detailed description

The purpose of the study : to enroll about 50 patients operated on because of a low-risk intrathyroidal papillary thyroid cancer with diameter of 11-20mm, and in whom postoperative thyroglobulin levels are of low level. Methods: either to follow-up patients according to the study protocol without radioiodine treatment or to give a radioiodine treatment with a dose of 1.1 GBq according to the normal Finnish treatment protocol for papillary thyroid cancer to those patients who themselves preferred to have a normal postoperative treatment.

Interventions

OTHERWith radioiodine treatment

Postoperative radioiodine not given

PROCEDUREWith postoperative radioiodine treatment

Postoperative radioiodine given

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Masking description

No masking.

Intervention model description

Patients with low risk papillary thyroid cancer either received a radioiodine treatment according to the normal Finnish treatment schedule or were schedulded for only follow-up .

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* low risk papillary intrathyroidal thyroid cancer with diameter of 11-20mm * no lymphnode metastases

Exclusion criteria

* high risk papillary cancer * mutlifocal papillary cancer

Design outcomes

Primary

Measure	Time frame	Description
Event free situation during follow-up event free /disease free	10 yrs	Without any treatmment

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026